Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Uptake and 24-month outcomes of dolutegravir- versus lopinavir-based second-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study and emulated target trial

Brown JA. et al, (2025), Open Forum Infectious Diseases

Retrospective cohort analysis of antiretroviral therapy initiation timelines and clinical outcomes in adults with HIV and TB disease in KwaZulu-Natal, South Africa.

Jansen van Vuuren CJ. et al, (2025), Int J STD AIDS

The PRINCIPLE randomised controlled open label platform trial of hydroxychloroquine for treating COVID19 in community based patients at high risk.

Hobbs FDR. et al, (2025), Sci Rep, 15

Cost and clinical flow of point-of-care urine tenofovir testing for treatment monitoring among people living with HIV initiating ART in South Africa.

Wang M. et al, (2025), J Int AIDS Soc, 28

Point-of-care HIV viral load testing in a community antiretroviral therapy delivery programme: a randomised controlled trial (PHILA)

Dorward J. et al, (2025)

Impact of increasing CD4 count threshold eligibility for antiretroviral therapy initiation on advanced HIV disease and tuberculosis prevalence and incidence in South Africa: an interrupted time series analysis.

Asare K. et al, (2025), BMJ Glob Health, 10

A viro-immunological model to characterize the antiviral effect of molnupiravir in SARS-CoV-2-infected outpatients: implication for treatment duration.

Nguyen BT. et al, (2025), J Infect Dis

Acceptability and perspectives on clinic-based urine tenofovir testing for antiretroviral therapy adherence monitoring: qualitative findings from a randomized controlled trial in South Africa

Bardon AR. et al, (2025)

Risk of major adverse cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: emulated target trials using routine, de-identified data from South Africa

Dorward J. et al, (2025)

Uptake and 24-month outcomes of dolutegravir- versus lopinavir-based second-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study and emulated target trial

Brown JA. et al, (2025)

Retrospective cohort analysis of antiretroviral therapy initiation timelines and clinical outcomes in adults with HIV and TB disease in KwaZulu-Natal, South Africa

Jansen van Vuuren CJ. et al, (2025)

Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART.

Naidoo K. et al, (2025), South Afr J HIV Med, 26

Improving the quality of interpersonal care in HIV programmes

Tlhaku K. and Dorward J., (2024), Lancet HIV

High burden of Human Papillomavirus and pre-malignant cervical lesions among women starting HIV treatment in KwaZulu-Natal, South Africa

Naicker N. et al, (2024), Sexually Transmitted Infections

Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.

Hobbs FR. et al, (2024), J Infect

Healthcare worker perspectives on adaptations to differentiated anti-retroviral therapy delivery during COVID-19 in South Africa: A qualitative inquiry

Tlhaku K. et al, (2024), PLOS Global Public Health, 4

Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.

Dorward J. et al, (2024), J Acquir Immune Defic Syndr, 95, e8 - e11

Early HIV viral suppression associated with subsequent 12‐month treatment success among people living with HIV in South Africa

Violette LR. et al, (2024), HIV Medicine

Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.

Hayward G. et al, (2024), J Infect

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Standing JF. et al, (2024), Nature Communications, 15

Load More

Include forthcoming?